Indaptus Therapeutics Inc banner

Indaptus Therapeutics Inc
NASDAQ:INDP

Watchlist Manager
Indaptus Therapeutics Inc Logo
Indaptus Therapeutics Inc
NASDAQ:INDP
Watchlist
Price: 1.87 USD 1.08%
Market Cap: $4.2m

Relative Value

INDP doesn't have a meaningful market cap.

There is not enough data to reliably calculate the relative value of INDP.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

INDP Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Multiples Across Competitors

INDP Competitors Multiples
Indaptus Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Indaptus Therapeutics Inc
NASDAQ:INDP
4.2m USD 0 -0.2 0.1 0.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
403.4B USD 6.6 95.8 15.7 21.8
US
Amgen Inc
NASDAQ:AMGN
203.8B USD 5.5 26.2 15 15
US
Gilead Sciences Inc
NASDAQ:GILD
184.4B USD 6.3 21.7 13.5 16.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
127.1B USD 10.6 32 24.2 25.3
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.5B USD 5.7 18.1 13.6 15.5
AU
CSL Ltd
ASX:CSL
69.4B AUD 3.2 35.2 11.6 14.6
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8 -66.6 -60.1
NL
argenx SE
XBRU:ARGX
39B EUR 11.1 35.7 38.8 39.6
P/S Multiple
Revenue Growth P/S to Growth
US
Indaptus Therapeutics Inc
NASDAQ:INDP
Average P/S: 3 369 303.3
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.5
3%
1.8
US
Gilead Sciences Inc
NASDAQ:GILD
6.3
5%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.6
11%
1
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
10%
0.6
AU
CSL Ltd
ASX:CSL
3.2
4%
0.8
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
NL
argenx SE
XBRU:ARGX
11.1
27%
0.4
P/E Multiple
Earnings Growth PEG
US
Indaptus Therapeutics Inc
NASDAQ:INDP
Average P/E: 37.8
Negative Multiple: -0.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
95.8
97%
1
US
Amgen Inc
NASDAQ:AMGN
26.2
20%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
21.7
16%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
32
16%
2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.1
13%
1.4
AU
CSL Ltd
ASX:CSL
35.2
10%
3.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
NL
argenx SE
XBRU:ARGX
35.7
32%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Indaptus Therapeutics Inc
NASDAQ:INDP
Average EV/EBITDA: 16.6
0.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.7
12%
1.3
US
Amgen Inc
NASDAQ:AMGN
15
10%
1.5
US
Gilead Sciences Inc
NASDAQ:GILD
13.5
9%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.2
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.6
18%
0.8
AU
CSL Ltd
ASX:CSL
11.6
7%
1.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
NL
argenx SE
XBRU:ARGX
38.8
50%
0.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Indaptus Therapeutics Inc
NASDAQ:INDP
Average EV/EBIT: 18.6
0.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
21.8
24%
0.9
US
Amgen Inc
NASDAQ:AMGN
15
3%
5
US
Gilead Sciences Inc
NASDAQ:GILD
16.6
13%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.3
16%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.5
23%
0.7
AU
CSL Ltd
ASX:CSL
14.6
10%
1.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
NL
argenx SE
XBRU:ARGX
39.6
56%
0.7
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett